Providers
Neurologist Dr. Curtis Schreiber presents at Alzheimer’s clinical trials conference
Curtis P. Schreiber, M.D., a board-certified neurologist and dementia specialist with the Missouri Memory Center at Citizens Memorial Hospital (CMH) in Bolivar, recently attended the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego. While there, Dr. Schreiber presented information from studies conducted at the Missouri Memory Center and the CMH Research Department.
Dr. Schreiber served as the lead author and presenter of a poster titled, “Stability and Improvement in Early Alzheimer’s Disease with Lecanemab: Sub-analysis From a United States Multicenter, Retrospective Real-World Study.” The research is part of the LEADER study, a nationwide project conducted at 12 clinical research sites, including the Missouri Memory Center.
The LEADER study examined real-world outcomes for patients treated with Leqembi, a newer medication approved by the U.S. Food and Drug Administration (FDA) for early Alzheimer’s disease. Results presented at the conference showed that in just over one year (375 days), 84% of patients remained stable and 6.7% showed improvement.
“The goal of these new treatments is to slow the progression of Alzheimer’s disease,” Dr. Schreiber said. “The early results of the LEADER study confirm that Leqembi works just as well in everyday medical practice as it did in the clinical trials that led to its FDA approval.”
Dr. Schreiber also contributed as an author on a second poster presentation titled, “P-tau217 Testing Impact on Patient Management in a Racially and Ethnically Diverse Population: Six-Month Follow-Up in a Randomized Clinical Utility Study.” This nationwide study examined how new blood tests can help physicians more accurately diagnose Alzheimer’s disease. The CMH Research Department and Missouri Memory Center enrolled more patients in the study than any other participating site.
Beyond research, the Missouri Memory Center is already using these advanced blood tests in daily patient care to help detect Alzheimer’s disease earlier and more accurately.
“The new world of diagnosing and treating Alzheimer’s disease isn’t coming — it’s already here,” Dr. Schreiber said. “For the first time in history, treatments can slow the mental and physical decline caused by Alzheimer’s. New blood tests allow us to detect changes in the brain using just a drop of blood, helping us diagnose the disease at its earliest and mildest stages. The old approach of ‘wait and see’ is no longer good enough. When it comes to Alzheimer’s disease, months matter. With the tools and treatments we now have, early action can make a real difference.”
About Dr. Schreiber
Dr. Schreiber earned his medical degree and completed his neurology residency at Mayo Clinic in Rochester, Minnesota. He is board certified in neurology by the American Board of Psychiatry and Neurology. He has 35 years of experience and started Missouri Memory Center at CMH in 2015. Dr. Schreiber has served as principal investigator for 14 Alzheimer’s disease clinical trials conducted through the CMH Research Department.
Missouri Memory Center, CMH Neurology and Headache Center, and CMH Research Department are located at 1245 N. Butterfield Road, Suite C1, in Bolivar. To schedule an appointment at Missouri Memory Center or for information about Alzheimer’s disease research studies at CMH, call 417-327-3530.
